A team of researchers has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals than previously reported with rebound symptoms and test-positivity after taking Paxlovid.